Innoviva, Inc. Market Cap 2010-2024 | INVA

Innoviva, Inc. market cap history and chart from 2010 to 2024. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. Innoviva, Inc. market cap as of February 24, 2025 is $1.13B.
Sector Industry Market Cap Revenue
Medical Large Cap Pharma $1.132B $0.310B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly and Company (LLY) US $828.397B 67.21
Novo Nordisk A/S (NVO) DK $395.262B 26.77
Johnson & Johnson (JNJ) US $390.756B 16.25
AbbVie Inc. (ABBV) US $356.743B 19.97
Roche Holding AG (RHHBY) CH $264.174B 0.00
Merck & Co., Inc. (MRK) US $226.402B 11.72
Novartis AG (NVS) CH $223.511B 14.00
Pfizer Inc. (PFE) US $149.042B 8.46
Sanofi (SNY) $138.211B 13.09
Bayer Aktiengesellschaft (BAYRY) DE $22.635B 3.62